Objective: To evaluate the association between selective serotonin reuptake inhibitor (SSRI) and selective serotonin and norepinephrine reuptake inhibitor (SNRI) use and risk of fractures in older adults.
over other antidepressants (eg, tricyclics) is due to their broad indications, safer side effect profile, and efficacy. 4 However, the use of SSRIs may be associated with a higher risk for all types of fractures compared with no SSRI use, which may be a particular concern in older patients. [5] [6] [7] [8] Several guidelines mention the risk of fractures for SSRI use in the elderly: UK guidance on the use and safety of SSRIs indicates a small increased risk of fractures, 9 and the 2015 update of the Beers criteria also lists SSRIs as inappropriate medications in older adults, based on falls risk. 10 Although studies such as the population-based Canadian Multicenter Osteoporosis study showed an increased risk, which led to a recommendation that bone health be assessed in patients treated with SSRIs, 11 a recent systematic review of Gebara et al on the risk of falls could not show causality between SSRI use and the former, stating that there is a lack of evidence to support changes in the current treatment guidelines on the use of SSRIs in older adults. 12 Another group of antidepressants that is growing in popularity is selective serotonin and norepinephrine reuptake inhibitors (SNRIs);
however, little is known about their associated risk of fractures.
This group of medications is increasingly prescribed in the elderly population for the treatment of a range of conditions such as depression, anxiety, diabetic neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. 13 Venlafaxine and Duloxetine are 2 SNRIs that are commonly prescribed. Venlafaxine is now reported to be the sixth most frequently prescribed medication for the treatment of depression in older people. 14 Several systematic reviews on the association of SSRI use and risk of fractures have been published previously, with the most recent being by Rabenda et al in 2013. 8 We conducted an initial scoping review, which found that a considerable number of new, large, and higher quality studies had been published since, indicating that an updated review would be appropriate.
Thus, considering an increasing rate of SSRI and SNRI prescription, a lack of studies on their comparative safety profile in older adults and a considerable number of new published studies since the last systematic review, we conducted a systematic review and meta-analysis with meta-regression. The specific research questions we sought to address were as follows: (1) what is the association between SSRI and SNRI use versus nonuse, on the risk of fracture in older adults? And (2) what is the effect of age on this association?
| METHODS
We conducted a systematic review and meta-analysis according to the Cochrane recommendations. 15 The review protocol was registered with the international register of systematic review protocols on
PROSPERO (CRD42016052926). We used the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) framework for reporting the results. 16 
| Eligibility criteria
To be included in our review, studies had to meet the following criteria:
• Population: adults on an SSRI or SNRI, with or without a formal diagnosis of depression.
• Exposure: SSRI or SNRI use-Fluoxetine, Citalopram, Escitalopram, Paroxetine, Sertraline, Fluvoxamine, Venlafaxine, and Duloxetine (a full list is provided online in the Supporting Information).
• Comparison: none or some other form of antidepressant treatment.
• Primary outcome: fracture (any type of fracture at any anatomical sites either self-reported or identified in the hospital records).
• Study design: randomized-controlled trials, case-control (eg, patients with a fracture compared with patients without a fracture), and cohort studies (eg, SSRI users compared with non SSRI users).
We included studies using any dose or duration of use of SSRI or SNRI and recorded these factors as potential modifiers of treatment effect.
For completeness when searching for studies, we also included those comparing SSRIs to SNRIs, different types of SSRIs/SNRIs, and different doses of SSRI/SNRI. These studies are described in the text but have been excluded from any pooled statistical analysis (see below).
| Search strategy and data sources
A specialist librarian in systematic reviews assisted with the literature search. We performed a systematic search for articles without language restrictions in the following electronic bibliographic databases: Key points
• SSRIs are the first choice of antidepressants in elderly patients with depression. They are associated with higher risk of fractures. Depression plays an independent role in increased risk of fractures.
• Our study found that age does not increase the risk of fractures associated with SSRIs use. Long-term use of SSRIs leads to higher risk of fractures.
• A number of methodological limitations of the published trials suggest the actual risk may be higher than our estimate.
inhibitor," "serotonin norepinephrine reuptake inhibitor," "fracture,"
"osteoporosis," "osteopenia," and "bone mineral density." (see the Supporting Information for an example of the complete MEDLINE search terms). Additionally, reference lists from identified papers and reviews were checked for additional relevant studies. All companion articles of the included studies were also examined. If more than one publication described the same study, it was treated as one study.
The full articles relating to any identified conference abstracts were obtained whenever possible. Literature search results were uploaded to the Endnote X7 reference management software package.
| Study selection
We used a 2-step approach to study selection. First, 2 reviewers (V.K.
and J.H.) independently examined the references (titles and abstracts) based on the eligibility criteria. Second, full texts of the selected references were retrieved and read. At each step, differences in coding were resolved by consensus. We included conference abstracts if they provided sufficient data.
| Data collection process and items
One of the reviewers (V.K.) independently performed data extraction from each study using a standardized data collection form that included author, publication date, country, study design, setting, med- for any outcome, the most stringently adjusted estimate was selected.
Estimates of fracture risk for current and past SSRI and/or SNRI use were extracted separately, and an estimate of current use was used in a meta-analysis to derive an overall estimate across studies. 11, [18] [19] [20] For studies where multiple levels of DDD were investigated, results for the level closest to one DDD were selected. 19, 21 The primary outcome was fracture at any of the anatomical sites assessed in a study, which in most cases included multiple sites (eg, hip, wrist, or spine). [22] [23] [24] [25] Where results were reported for both osteoporotic and nonosteoporotic fractures, results for the former were used. 26 One of the authors (D.R.) checked the form and performed a quality control check by randomly selecting 60% of studies and conducting 100% verification of the data collected from these for meta-analysis.
| Risk of bias in individual studies
The quality of each included study was assessed independently by 2 reviewers (V.K. and J.H.) using the Newcastle-Ottawa scale, designed for case-control and cohort studies. 27 Low quality was defined as a Newcastle-Ottawa score <7 and high quality as a score ≥7
(maximum score 9). 5 
| Synthesis of results
We summarized the data in tables such as characteristics of included studies for case-control and cohort studies. When applying meta-analysis, we made an a priori assumption that studies were heterogeneous and adopted the Dersimonian-Laird random-effects model. 28 Depending on their design, studies reported effect sizes as ORs, hazard ratios, RRs, or standardized incidence ratios, but for analysis purposes we treated all forms of effect as approximating an RR and amenable to pooling because the baseline incidence rate of fractures was typically low. We combined effect estimates across case-control and cohort studies but also included a comparison between these designs. The I 2 statistic was used to measure heterogeneity. Analysis was conducted using the Stata v14 Metan and Metareg commands using an alpha value for statistical significance of 5%. 29 
| Meta-analyses
For our primary meta-analysis, we pooled studies regardless of the type(s) of SSRIs used or the site(s) of fracture studied but restricted the comparison to nonusers or past users of SSRIs (eg, we excluded studies directly comparing different antidepressants). We also conducted a sensitivity analysis using only the studies rated as high quality (NOS score ≥ 7) and subgroup meta-analyses (see Supporting
Information Table S4 ).
| Meta-regression
There was wide variation between studies in participant age profiles, ranging in means from 43 to 78 years. Therefore, to investigate the relationship between age and risk of fracture when using SSRIs, we conducted meta-regression analyses of (log) effect sizes on the average age (usually mean age but for one study the median 30 ) of the participants in each study. We then repeated this analyses including study design (cohort or case-control) and percentage male participants as covariates. Because of the limited number of studies for meta-regression, we did not include any further study-level covariates. 
| Number needed to harm

| RESULTS
We identified 2122 articles in the initial search, of which we reviewed 141 full articles ( Figure 1 ). Our final sample consists of 33 studies: 11
case-control studies and 22 cohort studies. No relevant randomized controlled studies were found. Sixteen studies were included from the previous systematic review, [20] [21] [22] [23] [24] [25] [26] 30, [32] [33] [34] [35] [36] [37] [38] [39] and 17 studies were identified as new in the databases (Figure 1 ). 42 with SSRIs of different adherence to the treatment, 50 and no comparator description. the most frequently reported anatomical site of a fracture followed by nonvertebral fractures and spine.
Six studies examined fracture incidence relative to SSRI daily dose (DDD) [19] [20] [21] 31, 39, 46 and 3 studies relative to affinity for 5-HTT. 24, 26, 39 Two studies reported the outcome for different follow-up periods. 49, 55, 56 The results of these cohorts were used independently in our meta-analyses.
| Quality of the studies
Of the 29 studies (conference abstracts were not included in the quality assessment), 26 were high quality (≥7) and 3 low quality (score < 7)
(Supporting Information Tables S2 and S3 Table S4 ).
Six studies examined the association between SNRI use and risk of fracture: 2 case-control and 4 cohort studies (Supporting Information Table S5 ). Effect of SNRI use was compared with nonuse, SSRI use, and tricyclics use. Two studies evaluated the effect of an individual SNRI (Venlafaxine). We did not conduct a meta-analysis on SNRIs due to their excessive heterogeneity and the limited number of studies. However, 2 studies reported a significantly increased risk associated with SNRI use (Table 3 ).
| Meta-regression
The meta-regression found no significant relationship between study effect size and average participant age, either without (OR = 1.006; P = .173) or with control for design type and gender balance (OR = 1.006; P = .175) (Figure 3 ). Design and gender were themselves not significant moderators of effect size (P = .602 and P = .640, respectively).
| Subgroup meta-analyses
Subgroup meta-analyses are presented in Table S4 (Supporting Information). In most subgroup analyses, the number of studies was small (<5) and heterogeneity was high. In line with the finding of the meta-regression, the association between SSRI use and the risk of fracture was similar in both case-control and cohort studies: RR 1.74, 95% CI 1.50 to 2.02, Results for individual SSRI medications were available from only 4 studies, and subgroup analysis showed only small differences in RRs with widely overlapping confidence intervals. However, the effect sizes were all well below the overall RR of 1.67 across all included studies, suggesting that this is an unrepresentative subset.
For the remaining subgroup analyses, the subcategory level effects likewise had highly overlapping confidence intervals in almost all cases, indicating either only small differences or that study numbers were too small to detect differences.
| Number needed to harm
On the basis of the overall pooled RR of 1.67 from our meta-analysis and baseline absolute fracture rates of 1.76% over 1 year, 3.26% over 2 years, and 8.06% over 5 years, 31 Despite age having a well-known association with fracture risk, 62 in meta-regression, we found the increase in risk from SSRI use to be much the same in all the studied age groups, from 40 years up to 80 years, and the same for males and females. Our meta-analysis thus indicated that SSRIs play an independent role from age and gender in increased risk of fracture. 6 
| Strengths and limitations
Our systematic review is the most comprehensive review to date on the use of SSRIs (and SNRIs) and the risk of fracture. The last metaanalysis on SSRIs was published in 2013 and included 16 studies published up to April 2011. 8 The great majority of the studies we included were individually statistically significant, but nonetheless, there was high heterogeneity in effect size and some evidence of possible publication bias against smaller, nonsignificant studies.
Although the large majority of studies were rated high quality, the cohort studies generally fell down on giving details of exposure and the case-control studies on details of exposure and nonresponse rate.
The control condition was frequently poorly described and differed across studies but in most cases combined nonusers of antidepressants with users of other types of antidepressants. This may have led to some degree of underestimation of the fracture risk for SSRIs compared with an entirely antidepressant free population. We did not have individual patient data for meta-regression, so were limited to using study mean ages and gender balance, which will have limited our power to detect an association with risk. The limited number of the studies on SNRIs use and a risk of fracture did not allow us to conduct a meta-analysis and to provide their safety profile.
We found no relevant randomized controlled trials; hence, our review is based entirely on observational studies that have the potential for bias. We extracted the data adjusted for confounders such as osteoporotic risk factors (eg, BMI and previous fracture), study design, methodological quality, age, type of fracture, and duration of the treatment. However, there is still a risk of unobserved bias. For example, as Gebara et al indicate, a study design based on an administrative database 11, 45 will not adequately capture the diagnosis of depression. 12 An absence of randomization in observational studies also introduces the risk of allocation bias. In this context, older patients with higher risk of falls tend to have SSRIs or SNRIs prescribed, instead of other antidepressants (eg, tricyclic antidepressants). We found indications of publication bias against smaller nonsignificant studies, but this is unlikely to fully account for our overall result, derived mostly from a substantial number of very large observational investigations.
There were considerable differences in design between studies, including variations in study design, populations, comparison groups, SSRI medications, doses and duration, and nonadjustment (or nonreporting) of important variables. However, we excluded 10 studies from meta-analysis that were markedly different in quality of reporting, population, or selection of comparison group (eg, tricyclics).
We were limited in our ability to investigate the effects of this heterogeneity on study results because of the number of studies and the available information on each. Most of the subgroup analyses were based on very small numbers of studies (2, 3, or 4) , and results for these should be treated with considerable caution, as the addition of just 1 extra studyparticularly given the high heterogeneity-could cause a substantial change in the effect estimate or confidence interval. 
